Company Overview
American HealthCare Capital is pleased to introduce a development-stage biopharmaceutical company with a novel, patented, small-molecule therapeutic agent for brain cancers. The agent selectively targets and inhibits a novel transcription factor that is highly expressed in glioblastomas and other brain tumors. In tumor cell-based and animal models of glioblastoma, the agent is effective in selectively killing tumor cells, alone and in combination with other targeted therapies. The drug is orally available and attains therapeutically relevant concentrations in the brain tissue of non-human primates. The key value drivers for this therapy include:
- Current approaches to treat brain cancers are highly invasive, have significant side effects, and are largely ineffective in the long term.
- This agent has high affinity for and selective inhibition of a novel, key transcription factor that is expressed selectively in brain tumors but not in normal, mature neuronal cells.
- Strong pre-clinical evidence of efficacy and favorable pharmacokinetics in the most relevant models, including oral bioavailability and concentration in brain tissue.
- A favorable pre-clinical safety profile at relevant clinical doses
- A strong intellectual property position with issued patents in the US and all major markets
- Phase 1 clinical trial set to begin Q1 2026.
- A recent raise of $4 million from two private investors and a $432,000 grant
- $1.6 million in commitments from three brain cancer-focused foundations
The Opportunity
The Company is seeking an acquisition, strategic partnership, or additional capital of $4 million to fund the significant initial and expanded clinical development programs for this critical therapeutic approach, ensuring its rapid availability to patients who need better treatments for brain cancer.
Asking Price
The price and structure of any transaction are to be determined.
